FDA approves first gene therapy ever in US – WNDU-TV
WNDU-TV |
FDA approves first gene therapy ever in US
WNDU-TV The Food and Drug Administration has approved the first gene therapy ever available in the United States. It’s called CAR-T cell gene therapy, and it’s giving young leukemia patients hope after they’ve run out of options. Each dose of the drug is … |
Yahoo News |
New gene editing tech promises to be even better than CRISPR
Yahoo News Just when we were getting used to the CRISPR/Cas9 gene editing revolution, a new “fourth-generation” DNA base editor has come along — offering a new way to modify the genetic code that may be safer in terms of reducing potential mistakes. Base editing … The Latest Guide to Understanding CRISPR-Cas9Edgy Labs (blog) ‘Designer babies’ won’t be a fad. It’s too hard to create them.USA TODAY Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in AugustMadison.com |
Nasdaq |
Roche blood test could help ‘personalize’ cancer immunotherapy
Nasdaq Evidence shows that tumours with more mutations are more likely to respond to immunotherapy, Roche said, adding that it hoped its and Foundation’s new test would improve measuring TMB where invasive tumour biopsies that can be tough to evaluate are … |
Bloomberg |
Kymriah, First CAR–T Therapy Approved: 4 Pharma Stocks in Focus
Nasdaq Kymriah, formerly CTL019, is the first chimeric antigen receptor T cell (CAR-T) therapy approved. A novel immunocellular therapy and one-time treatment, Kymriah uses patient’s T cells to fight cancer. While the long-term impact of the treatment is yet … FDA Vows Modernization to Keep Up With Biotech AdvancesBloomberg |
Bloomberg |
Kymriah, First CAR–T Therapy Approved: 4 Pharma Stocks in Focus
Nasdaq Kymriah, formerly CTL019, is the first chimeric antigen receptor T cell (CAR-T) therapy approved. A novel immunocellular therapy and one-time treatment, Kymriah uses patient’s T cells to fight cancer. While the long-term impact of the treatment is yet … FDA Vows Modernization to Keep Up With Biotech AdvancesBloomberg |
Bloomberg |
Kymriah, First CAR–T Therapy Approved: 4 Pharma Stocks in Focus
Nasdaq Kymriah, formerly CTL019, is the first chimeric antigen receptor T cell (CAR-T) therapy approved. A novel immunocellular therapy and one-time treatment, Kymriah uses patient’s T cells to fight cancer. While the long-term impact of the treatment is yet … FDA Vows Modernization to Keep Up With Biotech AdvancesBloomberg |
Bloomberg |
Kymriah, First CAR–T Therapy Approved: 4 Pharma Stocks in Focus
Nasdaq Kymriah, formerly CTL019, is the first chimeric antigen receptor T cell (CAR-T) therapy approved. A novel immunocellular therapy and one-time treatment, Kymriah uses patient’s T cells to fight cancer. While the long-term impact of the treatment is yet … FDA Vows Modernization to Keep Up With Biotech AdvancesBloomberg |